Oncology

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Retrieved on: 
Tuesday, April 9, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, CER, Nadofaragene firadenovec, AER, Audit, Growth, Alexandra, Countess of Frederiksborg, Ferring, Falk, Partnership, ESG, Mortality, Nordic Investment Bank, PPH, Committee on Finance, Annual report, Count, Vice, Food, Management

EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.

Key Points: 
  • EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.
  • The year marked a major turning-point for Ferring with the launch of two innovative first-in-class medicines in the United States.
  • Ferring is evolving to make the most of these opportunities, and there were a number of significant changes to the senior leadership.
  • Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “The launch of two groundbreaking medicines in the US, along with the other important changes in 2023, mark the start of an exciting new phase of growth for Ferring.

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Azacitidine, VTX, Phase, Wake Forest University, Patient, Trial of the century, Survivor, Acute myeloid leukemia, Cancer, AML, Pharmaceutical industry

Accordingly, we can start the Phase I/II combo-study very soon.

Key Points: 
  • Accordingly, we can start the Phase I/II combo-study very soon.
  • The aim for conducting this study is to judge if DFP-10917 combined with VTX is to show superiority to the standard chemotherapy (azacitidine combined with VTX) for AML.
  • This combo-study shall be done by major clinical sites in US like Wake Forest University, expertise with clinical study of novel chemotherapy for AML.
  • Please take notice of our own innovative approach for miserable cancer patients and contact with us.

Exact Sciences Schedules First Quarter 2024 Earnings Call

Retrieved on: 
Monday, April 8, 2024
General Health, Health, Oncology, Medical Supplies, Webcast

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024.

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024.
  • Following the release, company management will host a webcast and conference call at 5 p.m.
  • ET to discuss financial results and business progress.

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Retrieved on: 
Monday, April 8, 2024
Health, Radiology, Pharmaceutical, Clinical Trials, Oncology, Toxicity, Therapy, Neoplasm, AACR, DNA, Prostate cancer, PSMA, MEK, Pharmaceutical industry

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to identify synergistic combinations of known anticancer drugs with 177Lu-rhPSMA-10.1 radioligand therapy, and from a preclinical efficacy analysis of the lead novel drug combination for the treatment of prostate cancer.

Key Points: 
  • Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to identify synergistic combinations of known anticancer drugs with 177Lu-rhPSMA-10.1 radioligand therapy, and from a preclinical efficacy analysis of the lead novel drug combination for the treatment of prostate cancer.
  • “Combination approaches are of increasing interest among the medical community, as we know tumors are heterogeneous and some prostate cancer cells do not express PSMA.
  • Results from this preclinical study presented at AACR demonstrated a synergistic therapeutic effect between 177Lu-rhPSMA-10.1 and an MEK inhibitor.
  • This may be due to inhibition of the MEK-MAPK pathway during DNA damage response, resulting in radiosensitization of cancer cells to 177Lu-rhPSMA-10.1.

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

Mirion Dosimetry Services Announces Availability of New InstadoseVUE Wireless Radiation Dosimeter

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Health, Biometrics, Other Health, Nuclear, Radiology, Energy, Oncology, Other Science, Medical Devices, General Health, Hospitals, Health Technology, Science, Radiation, Communication, Risk, VUE, Safety, Multimedia, Medical imaging

Mirion Dosimetry Services , a Mirion Medical company, today announced commercial availability of its innovative new Instadose®VUE wireless dosimeter .

Key Points: 
  • Mirion Dosimetry Services , a Mirion Medical company, today announced commercial availability of its innovative new Instadose®VUE wireless dosimeter .
  • View the full release here: https://www.businesswire.com/news/home/20240408854096/en/
    The Instadose®VUE wireless dosimeter from Mirion Dosimetry Services, a Mirion Medical company.
  • “Launching the InstadoseVUE dosimeter signifies more than just the release of a product; it embodies our vision to redefine radiation safety in workplaces.
  • Electronic display screen for expanded user visibility, engagement, and compliance
    “The InstadoseVUE wireless dosimeter is not just for radiation workers and medical imaging personnel,” says Bart LeClou, VP of International Sales for Mirion Dosimetry Services.

Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences

Retrieved on: 
Monday, April 8, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, G protein-coupled receptor, Multimedia, Gq alpha subunit, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240408769768/en/
    Anthony Johnson & Sean A. MacDonald (Photo: Domain Therapeutics)
    Location: Metro Toronto Convention Centre (North Building), Toronto, Canada

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

Retrieved on: 
Monday, April 8, 2024
FDA, Pharmaceutical, Health, Oncology, Acute lymphoblastic leukemia, Growth, Disease, Caregiver, New Drug Application, Patient, Nelarabine, NDA, Breast, Leukemia, Agency, Cancer, T-cell leukemia, Adenocarcinoma, Ovary, Food, Pharmaceutical industry

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.

Key Points: 
  • Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.
  • The Agency assigned a Prescription Drug User Fee Act (“PDUFA”) action date of November 30, 2024.
  • “With this NDA acceptance for SH-201, we are a step closer to providing an alternative treatment to thousands of U.S. patients diagnosed with leukemia and other cancers who do not currently have the option of an oral liquid,” said Sharon Cunningham, Chief Executive Officer and Co-Founder of Shorla Oncology.
  • The company recently raised $35 million in Series B funding that has allowed Shorla to accelerate the growth of its oncology portfolio.

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Medical Devices, Health, Genetics, Clinical Trials, Biotechnology, Survival, Patient, RNA, DNA, Cancer, University, Biology, Woman, AACR, Catalog, Breast cancer, MRD, DCIS, Blood, Medical imaging

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.

Key Points: 
  • Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.
  • In addition, the study showed the platform’s unique capability to distinguish low grade, less aggressive DCIS from invasive breast cancer with 87% sensitivity, at 90% specificity using a standard blood sample.
  • These results suggest the potential for Exai's platform to aid in tailoring adjuvant treatment for individual triple negative breast cancer patients.
  • oncRNAs are actively secreted from living cancer cells and are stable and abundant in the blood of cancer patients.